UNKNOWNNA

The Effect of Intravenous Nalbuphine on PONV With Intrathecal Morphine in Abdominoplasty.

How effectively intravenous nalbuphine can reduce the incidence of PONV after intrathecal administration of morphine in abdominoplastic surgery.

Sponsor

Assiut University

Enrollment

80 participants

Sites

1 locations

Start Date

March 2019

Completion

March 2020

Abdominal ObesityIntrathecal MorphineIntrathecal Morphine + Intravenous Nalbuphine

Enrollment & Timeline

UNKNOWN

Target enrollment (estimated)

Target N

participants

Sites

locations

Duration

18 months

total trial span

Rate

pts/month needed

Mar 2019Month 87 of 18Mar 2020

100% of trial timeline elapsed

At 1 sites, each site needs to enroll approximately 4.0 patients/month to hit the enrollment target on schedule.

Enrollment target is estimated. ClinicalTrials.gov does not provide real-time enrollment progress.

View on ClinicalTrials.gov

Ask AI

Primary Outcomes

postoperative nausea and vomiting

24 hours

A verbal descriptive scale (VDS) was used to assess the severity of PONV. ( no nausea=0, severe nausea= 10) by postoperative nausea and vomiting scale which range (o no nasuea to 10 sever vomating). A verbal descriptive scale (VDS) was used to assess the severity of PONV .

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

No linked publications found in PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

Fetching protocol from ClinicalTrials.gov…

UNKNOWNNA

The Effect of Intravenous Nalbuphine on PONV With Intrathecal Morphine in Abdominoplasty.

How effectively intravenous nalbuphine can reduce the incidence of PONV after intrathecal administration of morphine in abdominoplastic surgery.

Sponsor

Assiut University

Enrollment

80 participants

Sites

1 locations

Start Date

March 2019

Completion

March 2020

Abdominal ObesityIntrathecal MorphineIntrathecal Morphine + Intravenous Nalbuphine

Enrollment & Timeline

UNKNOWN

Target enrollment (estimated)

Target N

participants

Sites

locations

Duration

18 months

total trial span

Rate

pts/month needed

Mar 2019Month 87 of 18Mar 2020

100% of trial timeline elapsed

At 1 sites, each site needs to enroll approximately 4.0 patients/month to hit the enrollment target on schedule.

Enrollment target is estimated. ClinicalTrials.gov does not provide real-time enrollment progress.

View on ClinicalTrials.gov

Ask AI

Primary Outcomes

postoperative nausea and vomiting

24 hours

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

No linked publications found in PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

Eligibility

Min Age

20 Years

Max Age

50 Years

Sex

female

Healthy Volunteers

View full criteria

Inclusion Criteria:

* Patients undergoing abdominoplasty under spinal anesthesia
* American Society of Anesthesiologists (ASA) class I and II.

Exclusion Criteria:

* allergy to local anesthetics
* bleeding diatheses
* local infection or sepsis

The Effect of Intravenous Nalbuphine on PONV With Intrathecal Morphine in Abdominoplasty.

Enrollment & Timeline

Primary Outcomes

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

The Effect of Intravenous Nalbuphine on PONV With Intrathecal Morphine in Abdominoplasty.

Enrollment & Timeline

Primary Outcomes

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Eligibility

Trial Sites (1)